stockrow
Saturday 7 November 2026
Export ACET’s income statement to Excel — free account
Adicet Bio, Inc.
ACET Healthcare Biotechnology
Adicet Bio, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.0 million.
- EPS
- +63.4%
- Free cash flow
- +24.9%
Quarter to June 2026, against a year earlier
3.05
0.13
+4.45%
Follow ACET
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(71.73%) | (67.55%) | (72.19%) | (78.08%) | |
| (59.52%) | (56.62%) | (60.35%) | (63.62%) | ||
ROIC |
(1,133.54%) | (5,773.17%) | (2,135.23%) | (2,518.16%) | |
Return on Tangible Assets |
(108.97%) | (74.91%) | (79.47%) | (84.75%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(17.63) | (14.07) | (8.53) | (7.91) | |
Free Cash Flow |
(100.36) | (96.98) | (91.62) | (84.97) | |
Capital Expenditures |
(1.92) | (1.74) | (0.28) | (0.44) | |
| Other line items | |||||
Cash ROIC |
(47.15%) | (30.46%) | (32.90%) | (35.56%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(7,560.69) | (3,213.53) | (1,896.65) | (1,280.35) | |
Operating CF/Net income |
0.86 | 0.82 | 0.84 | 0.85 | |
Depreciation/Fixed assets |
0.13 | 0.14 | 0.16 | 0.16 | |
Capex/Depreciation |
(0.84) | (0.75) | (0.12) | (0.19) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(17.29) | (13.82) | (8.50) | (7.87) | |
Capex per Share |
(0.34) | (0.25) | (0.03) | (0.04) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates